Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The lipid nanoparticle (LNP) – host cell plasma membrane interface is the primary site of interaction for modern nucleic acid delivery systems, including mRNA vaccines and siRNA therapeutics. This interface is not a single molecule but a complex biological boundary where synthetic lipid assemblies meet the host cell's phospholipid bilayer. The interaction is typically initiated by the 'corona' of host proteins that coat the LNP upon entry into the bloodstream, most notably Apolipoprotein E, which directs the LNP to specific receptors like the Low-Density Lipoprotein Receptor (LDLR) (Akinc et al., 2010). Successful engagement at this interface triggers cellular uptake via endocytic pathways, which is a prerequisite for the subsequent endosomal escape and cytoplasmic delivery of the therapeutic cargo (Sahay et al., 2013). Engineering the components of the LNP to optimize this interaction is a central focus of nanomedicine to improve potency and reduce off-target effects. The plasma membrane acts as both a gateway and a barrier, requiring the LNP to possess specific physicochemical properties such as a neutral surface charge at physiological pH and an ionizable nature in acidic environments (Cullis & Hope, 2017). Disruptions or inefficiencies at this interface can lead to poor therapeutic efficacy or unwanted immune responses (Schoenmaker et al., 2021). Understanding the dynamics of this interface is crucial for developing next-generation delivery vehicles that can target specific tissues beyond the liver (Kulkarni et al., 2018).
Lipid nanoparticles typically utilize receptor-mediated endocytosis, often facilitated by the adsorption of Apolipoprotein E (ApoE) which binds to the Low-Density Lipoprotein Receptor (LDLR) on the host cell plasma membrane (Akinc et al., 2010). Once internalized, the ionizable lipids within the LNP undergo protonation in the acidic environment of the endosome, leading to membrane fusion and the release of nucleic acid cargo into the cytosol (Cullis & Hope, 2017).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lipid nanoparticle – host cell plasma membrane interface (LNP-PM interface).